Abstract
Ethical dilemmas arise with regularity, indeed daily, in the practice of rheumatology. As such, the practitioner must have the sensitivity and capacity to recognize them, reflect on their implications, and formulate responses directed at their mitigation. This article presents relevant ethical considerations (old and new) arising in the contemporary practice of rheumatology. A number of considerations stand out for their relevance to the rheumatic diseases. Conspicuous among these are the high costs associated with modern antirheumatic therapy, the complex relationship between physicians and the pharmaceutical industry, as well as challenges to the provision of care to patients suffering from complex chronic diseases. In this regard, patient autonomy is discussed, as is the need to insure for the provision of the time and resources for adequate patient education. The importance of such concerns goes beyond the patients’ themselves extending to the future generation of physicians who we will educate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Caplan L, Hoffecker L, Prochazka AV. Ethics in the rheumatology literature: a systematic review. Arthritis Rheum. 2008;59(6):816–21.
Mackenzie CR, Meltzer M, Kitsis EA, Mancuso CA. Ethical challenges in rheumatology: a survey of the American college of rheumatology membership. Arthritis Rheum. 2013;65(10):2524–32. This article discusses the important ethical issues identified by American rheumatologists. These include costs related to treatments, profiting from infusions, relationships with industry, and conflict of interest. A commitment to ethics education was suggested.
Bonafede M, Joseph GJ, Princic N, Harrison DJ. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. J Med Econ. 2013;16(9):1120–8. Using US claims administrative data, actual drug utilization was used to estimate treatment patterns and the annual cost per treated patient with different inflammatory conditions; etanercept was found to be the lowest cost per treated patient.
van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2011;63(1):65–78. This systematic review looked at different economic evaluations for biologics in patients with rheumatoid arthritis. Biologics were not cost effective in patients with no previous DMARD exposure and patients who failed methotrexate combination therapy or sequential DMARD administration (at a willingness to pay threshold of$ 50,000/Quality of life year). There was evidence of cost-effectiveness in patients who failed methotrexate monotherapy.
Hebert PC. Doing right: a practical guide to ethics for medical trainees and physicians. Ontario: Oxford University Press; 1995.
Ministry of Health and Longterm Care, Exceptional Access Program (EAP) EAP Reimbursement Criteria for Frequently Requested Drugs. 2014. Date accessed: October 12, 2014. http://www.health.gov.on.ca/en/pro/programs/drugs/eap_mn.aspx.
Sah S. Conflicts of interest and your physician: psychological processes that cause unexpected changes in behavior. J Law Med Ethics. 2012;40(3):482–7.
Collins J. Professionalism and physician interactions with industry. J Am Coll Radiol. 2006;3(5):325–32.
Sah S, Fugh-Berman A. Physicians under the influence: social psychology and industry marketing strategies. J Law Med Ethics. 2013;41(3):665–72. An article on the principles of influence that pharmaceutical companies may employ to change physicians behaviour. Evidence presented that these technqiues even influence physicians at a subconscious level, thus further education and policies to educate physicians is warranted.
McKeown E, Thorne JC, MacKenzie CR, McDonald-Blumer H. Ethical issues amongst Canadian rheumatologists: a comparison with American rheumatologists. Abstract submission to Canadian rheumatology association meeting for February 2015.
Canadian medical association code of ethics. 2004. Ottawa. Date accessed: October 10, 2014. http://policybase.cma.ca/dbtw-wpd/PolicyPDF/PD04-06.pdf.
Physicians’ relationships with industry: practice, education and research. College of Physicians and Surgeons of Ontario 2014. Date accessed: October 12, 2014. http://policyconsult.cpso.on.ca/wp-content/uploads/2014/03/Physicians-Relationships-with-Industry-Draft.pdf.
Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth. 2010;10(10):11–7.
Holbrook A, Lexchin J, Pullenayegum E, et al. What do Canadians think about physician-pharmaceutical industry interactions? Health Policy. 2013;112(3):255–63. A cross-sectional study of Canadian public regarding their views of physician-pharmaceutical interactions. The majority of scenarios posed in the study were rated as unacceptable by the public. Complete transparency by physicians of their relationships with pharmaceutical industry and finanicial reimbursement, if any, was recommended.
Wen L. Patients can’t trust doctors’ advice if we hide our financial connections with drug companies. BMJ. 2014;348:g167.
Marques FJ. Informed consent in rheumatology care practice. Rev Bras Reumatol. 2011;51(2):179–83. An article with a philosophical viewpoint that reviews the important historical aspects of informed consent. Reviews that a patient-physician relationship need be symmetrical, enhancing patient autonomy and that the explanations involving informed consent need to be take into consideration the patient’s sociocultural circumstances.
Baylis F, Downie J, Hoffmaster B, Sherwin S. eds. Health care ethics in Canada. 2nd edn. Toronto: Thomson Nelson, 2004: 192–207.
Townsend A, Adam P, Cox SM, Li LC. Everyday ethics and help-seeking in early rheumatoid arthritis. Chronic Illn. 2010;6(3):171–82.
Sugarman J, Bingham III CO. Ethical issues in rheumatology clinical trials. Nat Clin Pract Rheumatol. 2008;4(7):356–63.
Romain PL. Ethics: investigators’ interests: what should trial participants be told? Nat Rev Rheumatol. 2010;6(2):70–1.
Acknowledgments
Dr. McKeown would like to acknowledge Drs. Janet Pope and Ron MacKenzie for their contributions to the paper.
Compliance with Ethics Guidelines
ᅟ
Conflict of Interest
Emily J. Mckeown declares that she has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by the author.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Ethics
Rights and permissions
About this article
Cite this article
Mckeown, E.J. The ethical challenges in rheumatology. Curr Rev Musculoskelet Med 8, 107–112 (2015). https://doi.org/10.1007/s12178-015-9263-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12178-015-9263-1